arrow
J

John W. Ostrominski

Brigham and Women's Hospital and Harvard Medical School
H指数:18
被引数:1,869

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Finerenone and apparent treatment-resistant hypertension in heart failure with mildly reduced or preserved ejection fraction

非奈利酮对射血分数轻度降低或保留的心力衰竭患者中表观治疗抵抗性高血压的影响

2026-08-170
OAAI
Effects of Finerenone on Heart Failure Outcomes According to Baseline Heart Failure Risk in Chronic Kidney Disease and Type 2 Diabetes

根据慢性肾脏病和2型糖尿病基线心力衰竭风险,非奈利酮对心力衰竭结局的影响

2026-03-250
OAAI
Sex differences in cardiovascular-kidney-metabolic syndrome: the FINE-HEART pooled analysis

心血管-肾脏-代谢综合征中的性别差异:FINE-HEART合并分析

2026-03-010
PRE
Rationale and Design of the Cooperative Program for ImpLementation of Optimal Therapy in Heart Failure

优化心力衰竭治疗实施的合作计划的理念与设计

2026-02-062
OAAI
Finerenone and Cardiovascular Outcomes According to Baseline Kidney Function in Patients With Heart Failure

Finerenone及根据基线肾功能的心力衰竭患者心血管结局

2025-12-050
PRE
Timing of Cardiovascular and Kidney Benefits with Finerenone in Heart Failure and Chronic Kidney Disease with Type 2 Diabetes

Finerenone在心力衰竭和伴有2型糖尿病的慢性肾脏病中心血管和肾脏获益的时间点

JACC
IF0
2025-11-180
OAAI
Interplay of serum potassium and kidney function with finerenone in heart failure with mildly reduced or preserved ejection fraction: Findings from FINEARTS-HF

血清钾与肾功能对非奈利酮在轻度射血分数降低或保留的心力衰竭中的相互作用:FINEARTS-HF研究的结果

2025-10-020
OAAI
Finerenone according to insulin resistance in heart failure: Insights from the FINEARTS-HF trial

根据胰岛素抵抗在心力衰竭中的作用:FINEARTS-HF试验的见解

2025-09-080
OAAI
Effect of Finerenone on Morbidity and Mortality in CKD

非奈利酮对CKD患者发病率和死亡率的影响

2025-09-010
OA
Adiposity-Related Anthropometrics and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction

与肥胖度相关的体质测量指标及在轻度射血分数降低或保留的心力衰竭中的临床结局

JACC
IF0
2025-08-270
PRE
Natriuretic Peptides, Body Mass Index, and Clinical Outcomes in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

利钠肽、体重指数及轻度射血分数降低或保留的心力衰竭患者的临床结局

JACC
IF0
2025-08-270
PRE